Abstract:
Fluorescence studies indicate that a two-drug combination demonstrates the synergism in binding to human serum albumin if drugs prefer different protein binding sites. The formation of a drug complex with methylated β-cyclodextrin leads to an increase in albumin’s quenching and drug binding affinity, while the fluorescence quenching mechanism remains unchanged.